drugset / Trial / NCT07109284
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.
Timeline
- Start
- 2025-09
- Primary completion
- 2028-01
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KL-A167 | Unknown | 900 mg | Intravenous |
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 5 mg/kg | Intravenous |